Suppr超能文献

西咪替丁对人肝脏中扎来普隆代谢的抑制作用:亚细胞组分和精密肝切片的体外研究

Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices.

作者信息

Renwick A B, Ball S E, Tredger J M, Price R J, Walters D G, Kao J, Scatina J A, Lake B G

机构信息

TNO BIBRA International Ltd, Woodmansterne Road, Carshalton, Surrey SM5 4DS, UK.

出版信息

Xenobiotica. 2002 Oct;32(10):849-62. doi: 10.1080/00498250210158221.

Abstract
  1. The effect of cimetidine on the metabolism of zaleplon (ZAL) in human liver subcellular fractions and precision-cut liver slices was investigated. 2. ZAL was metabolized to a number of products including 5-oxo-ZAL (M2), which is known to be formed by aldehyde oxidase, N-desethyl-ZAL (DZAL), which is known to be formed by CYP3A forms, and N-desethyl-5-oxo-ZAL (M1). 3. Human liver microsomes catalysed the NADPH-dependent metabolism of ZAL to DZAL. Kinetic analysis of three microsomal preparations revealed mean (+/-SEM) S(50) and V(max) of 310 +/- 24 micro M and 920 +/- 274 pmol/min/mg protein, respectively. 4. Human liver cytosol preparations catalysed the metabolism of ZAL to M2. Kinetic analysis of three cytosol preparations revealed mean (+/-SEM), K(m) and V(max) of 124 +/- 14 micro M and 564 +/- 143 pmol/min/mg protein, respectively. 5. Cimetidine inhibited ZAL metabolism to DZAL in liver microsomes and to M2 in the liver cytosol. With a ZAL substrate concentration of 62 micro M, the calculated mean (+/-SEM, n = 3) IC50 were 596 +/- 103 and 231 +/- 23 micro M for DZAL and M2 formation, respectively. Kinetic analysis revealed that cimetidine was a competitive inhibitor of M2 formation in liver cytosol with a mean (+/-SEM, n = 3) K(i) of 155 +/- 16 micro M. 6. Freshly cut human liver slices metabolized ZAL to a number of products including 1, M2 and DZAL. 7. Cimetidine inhibited ZAL metabolism in liver slices to M1 and M2, but not to DZAL. Kinetic analysis revealed that cimetidine was a competitive inhibitor of M2 formation in liver slices with an average (n = 2 preparations) K(i) of 506 micro M. 8. The results demonstrate that cimetidine can inhibit both the CYP3A and aldehyde oxidase pathways of ZAL metabolism in the human liver. Cimetidine appears to be a more potent inhibitor of aldehyde oxidase than of CYP3A forms and hence in vivo is likely to have a more marked effect on ZAL metabolism to M2 than on DZAL formation. 9. The results also demonstrate that precision-cut liver slices may be a useful model system for in vitro drug-interaction studies.
摘要
  1. 研究了西咪替丁对扎来普隆(ZAL)在人肝脏亚细胞组分和精密肝切片中的代谢作用。2. ZAL代谢生成多种产物,包括已知由醛氧化酶形成的5-氧代-ZAL(M2)、已知由CYP3A亚型形成的N-去乙基-ZAL(DZAL)以及N-去乙基-5-氧代-ZAL(M1)。3. 人肝微粒体催化ZAL依赖NADPH代谢生成DZAL。对三种微粒体制剂的动力学分析显示,平均(±SEM)S(50)和V(max)分别为310±24μM和920±274pmol/min/mg蛋白。4. 人肝细胞溶胶制剂催化ZAL代谢生成M2。对三种细胞溶胶制剂的动力学分析显示,平均(±SEM)K(m)和V(max)分别为124±14μM和564±143pmol/min/mg蛋白。5. 西咪替丁抑制肝微粒体中ZAL代谢生成DZAL以及肝细胞溶胶中ZAL代谢生成M2。在ZAL底物浓度为62μM时,计算得出的生成DZAL和M2的平均(±SEM,n = 3)IC50分别为596±103和231±23μM。动力学分析表明,西咪替丁是肝细胞溶胶中M2生成的竞争性抑制剂,平均(±SEM,n = 3)K(i)为155±16μM。6. 新鲜切割的人肝切片将ZAL代谢生成多种产物,包括M1、M2和DZAL。7. 西咪替丁抑制肝切片中ZAL代谢生成M1和M2,但不抑制生成DZAL。动力学分析表明,西咪替丁是肝切片中M2生成的竞争性抑制剂,平均(n = 2种制剂)K(i)为506μM。8. 结果表明,西咪替丁可抑制人肝脏中ZAL代谢的CYP3A和醛氧化酶途径。西咪替丁似乎是醛氧化酶比CYP3A亚型更有效的抑制剂,因此在体内对ZAL代谢生成M2的影响可能比对DZAL生成的影响更显著。9. 结果还表明,精密肝切片可能是体外药物相互作用研究的有用模型系统。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验